SGX Announcements

SGX Announcements By Year: All | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018

11 Apr 2025 Cash Dividend / Distribution: Mandatory (FY2024)
11 Apr 2025 Notice of Annual General Meeting (FY2024)
19 Mar 2025 Change of Director’s Interest – Tan Kia King (19 Mar 2025)
11 Mar 2025 Media Release: Hyphens Pharma Obtains Exclusive Rights to Commercialise Metoject®
27 Feb 2025 Change of Director’s Interest – Tan Kia King (27 Feb 2025)
27 Feb 2025 Announcement: Result Briefing FY2024
25 Feb 2025 Financial Statements and Related Announcement: Full Yearly Results (2024)
12 Nov 2024 Announcement: Quarterly Business Update for the Third Quarter and Nine Months Ended 30 September 2024
19 Sep 2024 Media Release: Hyphens Pharma Launches Ceradan® Advanced Hand Balm, Specially Designed for Hand Eczema
28 Aug 2024 Media Release: Hyphens Pharma Wins Gold Award for Best Managed Board at Singapore Corporate Awards 2024
16 Aug 2024 Announcement: Results Briefing 1H 2024
14 Aug 2024 Financial Statements and Related Announcement: Half Yearly Results
06 Jun 2024 Announcement: Resignation of Mr. Timothy Chen, CEO of DocMed Technology and Pan-Malayan Pharmaceuticals
05 Jun 2024 Media Release: Hyphens Pharma licenses Amenalief® from Maruho for ASEAN
24 May 2024 Announcement: Minutes of Annual General Meeting Held on 25 April
14 May 2024 Announcement: Business Update for the First Quarter Ended 31 March 2024
13 May 2024 Share Buy Back – Daily Share Buy-Back Notice (Corrigendum to Notice dated 2 April 2024)
25 Apr 2024 Results of Annual General Meeting held on 25 April 2024
23 Apr 2024 Change of Director’s Interest – Chan Kiat (23 April 2024)
19 Apr 2024 Pre-AGM (FY2023): Address of Shareholders’ Queries & Proxy Form
09 Apr 2024 Cash Dividend / Distribution: Mandatory (FY2023)
09 Apr 2024 Notice of Annual General Meeting (FY2023)
02 Apr 2024 Share Buy Back – Daily Share Buy-Back Notice (2 April 2024)
02 Apr 2024 Change of Director’s Interest – Dr Tan Kia King (2 April 2024)
25 Mar 2024 Change of Director’s Interest – Chan Kiat (25 March 2024)
22 Mar 2024 Change of Director’s Interest – Dr Tan Kia King (22 March 2024)
12 Mar 2024 Media Release: Hyphens Pharma licenses Wynzora® Cream for ASEAN countries from MC2 Therapeutics
06 Mar 2024 FY2023 Full-Year Financial Results Briefing
29 Feb 2024 Media Release: Hyphens Pharma’s Ceradan range of products to enter major Middle East markets
27 Feb 2024 Financial Statements and Related Announcement: Full Yearly Results
06 Feb 2024 Media Release: Hyphens Pharma partners 7-Eleven to offer Ocean Health® supplements at selected convenience stores in Singapore
08 Dec 2023 Employee Stock Option/Share Scheme: Grant of Share Awards Pursuant to the Hyphens Share Plan
09 Nov 2023 Announcement: Quarterly Business Update for the Third Quarter and Nine Months Ended 30 September 2023
08 Nov 2023 Asset Acquisitions and Disposals: Completion Of Proposed Acquisition Of Tranche 1 Sale Shares Of 23% In Ardence Pharma Sdn Bhd
19 Oct 2023 Announcement : Analyst Briefing – Acquisition of Ardence Malaysia
17 Oct 2023 Asset Acquisitions and Disposals: Proposed Acquisition Of 58% Of The Share Capital In Ardence Pharma Sdn Bhd Over 3 Tranches
30 Aug 2023 Media Release: Nabota® successfully registered in Malaysia
17 Aug 2023 Announcement: Results Briefing 1H 2023
11 Aug 2023 Financial Statements and Related Announcement: Half Yearly Results
11 Aug 2023 Cash Dividend / Distribution: Mandatory
19 Jul 2023 Change of Substantial Shareholder’s Interest – Inomed Holding Pte Ltd
19 Jul 2023 Change of Director’s Interest – Mr Lim See Wah
19 Jul 2023 Change of Director’s Interest – Dr Tan Kia King
19 Jul 2023 Cessation of Substantial Shareholder’s Interest – Mr Tan Chwee Choon
05 Jun 2023 (Board Approval) Hyphens Pharma International – Appointment of CFO
24 May 2023 Announcement: Minutes of Annual General Meeting and Extraordinary General Meeting held on 26 April 2023
17 May 2023 Announcement: Hyphens Pharma to develop and commercialise Byfavo procedural sedation drug in Singapore
11 May 2023 Announcement: Business Update and Results Briefing for the First Quarter Ended 31 March 2023
28 Apr 2023 Employee Stock Option / Share Scheme: Allotment and Issuance of 422,000 New Ordinary Shares Under the Hyphens Performance Share Plan
26 Apr 2023 Results of Extraordinary General Meeting held on 26 April 2023
26 Apr 2023 Results of Annual General Meeting held on 26 April 2023
21 Apr 2023 Response to Queries from SIAS on Annual Report 2022
21 Apr 2023 Response to Substantial and Relevant Questions Received from Shareholders before Annual General Meeting
10 Apr 2023 Announcement of Cessation: Cessation of an Executive Director
10 Apr 2023 Cash Dividend / Distribution: Mandatory (FY2022)
10 Apr 2023 Notice of Extraordinary General Meeting
10 Apr 2023 Notice of Annual General Meeting (FY2022)
10 Apr 2023 Annual Reports and Related Documents
06 Mar 2023 Announcement: Results Briefing FY2022
28 Feb 2023 Financial Statements and Related Announcement: Full Yearly Results
10 Feb 2023 Media Release: Nabota® Successfully Registered in Singapore
21 Dec 2022 Media Release: Hyphens Pharma licenses Winlevi® for all 10 ASEAN countries from Cosmo Pharmaceuticals
05 Dec 2022 Media Release: Hyphens Pharma’s Meradan® Cream Launches in Indonesia
09 Nov 2022 Announcement: Quarterly Business Update for the Third Quarter and Nine Months Ended 30 September 2022
15 Sep 2022 Announcement: Hyphens Pharma’s TDF Blu Voile Sunscreen
17 Aug 2022 Announcement: Results Briefing 1H2022
11 Aug 2022 Financial Statements and Related Announcement: Half Yearly Results
06 Jun 2022 Announcement: Completion of Investment in DocMed Technology
31 May 2022 Sustainability Report 2021
27 May 2022 Corporate Presentation – DocMed
27 May 2022 Hyphens Attracts S$6 million Investment in DocMed Technology to Grow Digital Healthtech
12 May 2022 Announcement: Quarterly Business Update for the First Quarter Ended 31 March 2022
06 May 2022 Announcement of Cessation: Resignation of Chief Financial Officer
27 Apr 2022 Results and Minutes of Annual General Meeting held on 27 April 2022
21 Apr 2022 Response to Substantial and Relevant Questions Received from Shareholders before Annual General Meeting
12 Apr 2022 Cash Dividend / Distribution: Mandatory
12 Apr 2022 Notice of Annual General Meeting
12 Apr 2022 Annual Reports and Related Documents
02 Mar 2022 General Announcement: Results Briefing FY2021
23 Feb 2022 Financial Statements and Related Announcement: Full Yearly Results
26 Jan 2022 Change in Corporate Information: Change of Address of Share Registrar
13 Jan 2022 General Announcement: Corporate Presentation
10 Jan 2022 Hyphens Pharma Officially Launches WellAway, Singapore’s First HSA-Registered e-Pharmacy
14 Dec 2021 Hyphens Pharma Has Inked Exclusive Licensing Deal of Ustekinumab Biosimilar
09 Dec 2021 Asset Acquisitions and Disposals: Striking-Off of Indirect Wholly-Owned Subsidiary, DAC Pharmalab Pte Ltd
03 Dec 2021 Change of Director’s Interest – Mr Tan Chwee Choon
03 Dec 2021 Change of Director’s Interest – Dr Tan Kia King
03 Dec 2021 Change of Director’s Interest – Mr Lim See Wah
03 Dec 2021 Change of Substantial Shareholder’s Interest – Inomed Holding Pte Ltd
03 Dec 2021 Asset Acquisitions and Disposals: Completion of the Proposed Acquisition of 100% of the Issued Share Capital in Novem Group
19 Nov 2021 General Announcement: Receipt of Approval In-Principle from SGX-ST for the Listing and Quotation for New Ordinary Shares
16 Nov 2021 General Announcement: Acquisition of Novem & 3Q Business Update
12 Nov 2021 General Announcement: Quarterly Business Update for the Third Quarter and Nine Months Ended 30 September 2021
09 Nov 2021 Request for Lifting of Trading Halt
09 Nov 2021 Asset Acquisitions and Disposals: Entry into a Sale and Purchase Agreement Relating to the Proposed Acquisition
08 Nov 2021 Request for Trading Halt
10 Sep 2021 Change of Director’s Interest – Mr Lim See Wah
10 Sep 2021 Change of Substantial Shareholder’s Interest – Inomed Holding Pte Ltd
18 Aug 2021 General Announcement: Results Briefing 1H2021
11 Aug 2021 Financial Statements and Related Announcement: Half Yearly Results
17 May 2021 Sustainability Report 2020
12 May 2021 Change in Continuing Sponsor
12 May 2021 Quarterly Business Update: 1Q2021
28 Apr 2021 Results and Minutes of Annual General Meeting held on 28 April 2021
13 Apr 2021 Notice of Annual General Meeting
12 Apr 2021 Cash Dividend / Distribution: Mandatory
12 Apr 2021 Annual Reports and Related Documents
19 Mar 2021 Employee Stock Option / Share Scheme: Grant of Share Awards Pursuant to the Hyphens Share Plan
05 Mar 2021 Change of Director’s Interest – Dr Tan Kia King
05 Mar 2021 Change of Director’s Interest – Mr Lim See Wah
05 Mar 2021 Change of Substantial Shareholder’s Interest – Inomed Holding Pte Ltd
03 Mar 2021 General Announcement: Results Briefing FY2020
25 Feb 2021 Financial Statements and Related Announcement: Full Yearly Results
18 Jan 2021 Hyphens Pharma Appoints Exclusive Distributor in South Korea for TDF Fairence® T-Complex
07 Jan 2021 Hyphens Pharma Awarded e-Pharmacy Licence for WellAway Pharmacy
16 Nov 2020 General Announcement: Results Briefing 3Q2020
12 Nov 2020 Hyphens Pharma Broadens Ceradan Brand’s Outreach to Mainland China
11 Nov 2020 Financial Statements and Related Announcement: Third Quarter Results
05 Nov 2020 General Announcement: Change in Composition of the Board of Directors and Board Committees
05 Nov 2020 Announcement of Appointment: Appointment of an Independent Non-Executive Director
03 Nov 2020 Hyphens Pharma Expands Ocean Health Distribution to Sri Lanka
03 Sep 2020 Corporate Presentation
18 Aug 2020 Intangible Asset Portfolio Review
18 Aug 2020 General Announcement: Results Briefing 2Q2020
17 Aug 2020 Hyphens Pharma Inks Exclusive Partnership with SUTL to Distribute Ocean Health Products
13 Aug 2020 Financial Statements and Related Announcement: Second Quarter and/or Half Yearly Results
03 Aug 2020 Corporate Presentation at ASEAN Regional Healthcare Conference by DBS
03 Aug 2020 Hyphens Pharma Expands Proprietary Brands Portfolio with Hair Loss Products
24 Jul 2020 Change of Director’s Interest – Mr Tan Chwee Choon
22 Jul 2020 Change of Director’s Interest – Mr Tan Chwee Choon
15 Jul 2020 Change of Director’s Interest – Mr Tan Chwee Choon
13 Jul 2020 Hyphens Pharma Receives UK Patent for Ceradan Advanced
24 Jun 2020 Change of Director’s Interest – Mr Tan Chwee Choon
12 Jun 2020 Results and Minutes of Annual General Meeting held on 12 June 2020
08 Jun 2020 Response to Queries from SIAS on Annual Report 2019
02 Jun 2020 Change of Director’s Interest – Mr Tan Chwee Choon
01 Jun 2020 Change of Director’s Interest – Mr Tan Chwee Choon
26 May 2020 Sustainability Report 2019
21 May 2020 Notice of Annual General Meeting
14 May 2020 General Announcement: Results Briefing 1Q2020
11 May 2020 Cash Dividend / Distribution: Mandatory
11 May 2020 General Announcement: Update on FY2019 Proposed Final Dividend of S$0.01 per Share
11 May 2020 Financial Statements and Related Announcement: First Quarter Results
28 Apr 2020 Response to Query Regarding Trading Activity
27 Apr 2020 General Announcement – Voluntary Continuation of Quarterly Reporting and Deferment of Half-Yearly Reporting
17 Apr 2020 General Announcement: Change in Composition of the Board of Directors and Board Committees
17 Apr 2020 Announcement of Cessation: Resignation of an Independent Director
09 Apr 2020 General Announcement: Business Continuity During Covid-19 Pandemic
08 Apr 2020 Waiver: Extension of Time to Hold Annual General Meeting for Financial Year Ended 31 December 2019
08 Apr 2020 Annual Reports and Related Documents
03 Mar 2020 General Announcement: Hyphens Results Briefing FY2019
26 Feb 2020 Financial Statements and Related Announcement: Full Yearly Results
06 Feb 2020 General Announcement: TDF Fairence T-Complex has efficacy tests affirmed in Journal of Cosmetic Dermatology
17 Dec 2019 General Announcement: Hyphens Pharma inks Research Collaboration Agreement with the Institute of Chemical and Engineering Sciences
19 Nov 2019 General Announcement: Hyphens Results Briefing 3Q2019
14 Nov 2019 Financial Statements and Related Announcement: Third Quarter Results
05 Nov 2019 Announcement of Cessation: Resignation of General Manager
30 Aug 2019 Announcement of Appointment: Appointment of Chief Operating Officer
19 Aug 2019 General Announcement: Hyphens Results Briefing 2Q2019
13 Aug 2019 Financial Statements and Related Announcement: Second Quarter and/or Half Yearly Results
29 Jul 2019 Announcement of Appointment: Appointment of an Independent Non-Executive Director
22 Jul 2019 General Announcement: Ocean Health revamped, unveils new and refreshed look
10 Jul 2019 General Announcement: Hyphens Pharma launches New Ceradan Advanced
17 Jun 2019 General Announcement: Hyphens Pharma first to introduce bioabsorbable metallic implants to Vietnam
30 May 2019 General Announcement: Hyphens Pharma Signs Exclusive Distribution Agreement with Lundbeck for Vietnam
17 May 2019 General Announcement: Corporate Presentations – Hyphens Results Briefing 1Q2019
17 May 2019 General Announcement: Corporate Presentations – Hyphens Presentation Deck
17 May 2019 General Announcement: Corporate Presentations
15 May 2019 Employee Stock Option / Share Scheme: Grant of Share Awards Pursuant to the Hyphens Share Plan
13 May 2019 Financial Statements and Related Announcement: First Quarter Results
26 Apr 2019 Annual General Meeting: Results and Presentation Slides
18 Apr 2019 Asset Acquisitions and Disposals: Striking-Off Of Indirect Wholly-Owned Subsidiary – Ocean Healthcare (M) Sdn. Bhd.
10 Apr 2019 Notice of Annual General Meeting
10 Apr 2019 Annual Reports and Related Documents
10 Apr 2019 Cash Dividend/Distribution: Mandatory
21 Mar 2019 General Announcement: Hyphens Pharma Officially Opens Corporate Headquarters and Integrated Facility
06 Mar 2019 General Announcement: Hyphens Results Briefing 4Q2018 / FY2018
28 Feb 2019 Financial Statements and Related Announcement: Full Yearly Results
18 Feb 2019 General Announcement: Hyphens Pharma appoints Industry Veteran to head Dermatology Business Unit
05 Dec 2018 General Announcement: Entry into Memorandum of Understanding with Doctor Anywhere
13 Nov 2018 Financial Statements and Related Announcement: Third Quarter Results
29 Sep 2018 Change in Corporate Information: Change of Registered Office
29 Aug 2018 General Announcement: Corporate Presentation at INVEST Fair 2018
10 Aug 2018 Financial Statements and Related Announcement: Second Quarter and/or Half Yearly Results
23 May 2018 General Announcement: Tenancy Agreement with RBC Investor Services Trust Singapore Limited
18 May 2018 General Announcement: Balloting Result under Public Offer of Related Persons
18 May 2018 Disclosure of Interest/Changes in Interest of Director/Chief Executive Officer: Disclosure of interest by Executive Chairman and CEO – Mr Lim See Wah
18 May 2018 Disclosure of Interest/Changes in Interest of Director/Chief Executive Officer: Disclosure of interest by Executive Director – Mr Tan Chwee Choon
18 May 2018 Disclosure of Interest/Changes in Interest of Director/Chief Executive Officer: Disclosure of interest by Non-Executive Director – Dr Tan Kia King
18 May 2018 Disclosure of Interest/Changes in Interest of Substantial Shareholder(s)/Unitholder(s): Disclosure of interest by substantial shareholder – Inomed Holding Pte Ltd
18 May 2018 General Announcement: Hyphens Pharma International Makes Strong Listing Debut on the Catalist Board of the SGX-ST
17 May 2018 Equity – Listing Confirmation: Admission of 300,000,000 ordinary shares to the Official List of SGX-Catalist
17 May 2018 General Announcement: Balloting Results
11 Apr 2025 Cash Dividend / Distribution: Mandatory (FY2024)
11 Apr 2025 Notice of Annual General Meeting (FY2024)
19 Mar 2025 Change of Director’s Interest – Tan Kia King (19 Mar 2025)
11 Mar 2025 Media Release: Hyphens Pharma Obtains Exclusive Rights to Commercialise Metoject®
27 Feb 2025 Change of Director’s Interest – Tan Kia King (27 Feb 2025)
27 Feb 2025 Announcement: Result Briefing FY2024
25 Feb 2025 Financial Statements and Related Announcement: Full Yearly Results (2024)
12 Nov 2024 Announcement: Quarterly Business Update for the Third Quarter and Nine Months Ended 30 September 2024
19 Sep 2024 Media Release: Hyphens Pharma Launches Ceradan® Advanced Hand Balm, Specially Designed for Hand Eczema
28 Aug 2024 Media Release: Hyphens Pharma Wins Gold Award for Best Managed Board at Singapore Corporate Awards 2024
16 Aug 2024 Announcement: Results Briefing 1H 2024
14 Aug 2024 Financial Statements and Related Announcement: Half Yearly Results
06 Jun 2024 Announcement: Resignation of Mr. Timothy Chen, CEO of DocMed Technology and Pan-Malayan Pharmaceuticals
05 Jun 2024 Media Release: Hyphens Pharma licenses Amenalief® from Maruho for ASEAN
24 May 2024 Announcement: Minutes of Annual General Meeting Held on 25 April
14 May 2024 Announcement: Business Update for the First Quarter Ended 31 March 2024
13 May 2024 Share Buy Back – Daily Share Buy-Back Notice (Corrigendum to Notice dated 2 April 2024)
25 Apr 2024 Results of Annual General Meeting held on 25 April 2024
23 Apr 2024 Change of Director’s Interest – Chan Kiat (23 April 2024)
19 Apr 2024 Pre-AGM (FY2023): Address of Shareholders’ Queries & Proxy Form
09 Apr 2024 Cash Dividend / Distribution: Mandatory (FY2023)
09 Apr 2024 Notice of Annual General Meeting (FY2023)
02 Apr 2024 Share Buy Back – Daily Share Buy-Back Notice (2 April 2024)
02 Apr 2024 Change of Director’s Interest – Dr Tan Kia King (2 April 2024)
25 Mar 2024 Change of Director’s Interest – Chan Kiat (25 March 2024)
22 Mar 2024 Change of Director’s Interest – Dr Tan Kia King (22 March 2024)
12 Mar 2024 Media Release: Hyphens Pharma licenses Wynzora® Cream for ASEAN countries from MC2 Therapeutics
06 Mar 2024 FY2023 Full-Year Financial Results Briefing
29 Feb 2024 Media Release: Hyphens Pharma’s Ceradan range of products to enter major Middle East markets
27 Feb 2024 Financial Statements and Related Announcement: Full Yearly Results
06 Feb 2024 Media Release: Hyphens Pharma partners 7-Eleven to offer Ocean Health® supplements at selected convenience stores in Singapore
08 Dec 2023 Employee Stock Option/Share Scheme: Grant of Share Awards Pursuant to the Hyphens Share Plan
09 Nov 2023 Announcement: Quarterly Business Update for the Third Quarter and Nine Months Ended 30 September 2023
08 Nov 2023 Asset Acquisitions and Disposals: Completion Of Proposed Acquisition Of Tranche 1 Sale Shares Of 23% In Ardence Pharma Sdn Bhd
19 Oct 2023 Announcement : Analyst Briefing – Acquisition of Ardence Malaysia
17 Oct 2023 Asset Acquisitions and Disposals: Proposed Acquisition Of 58% Of The Share Capital In Ardence Pharma Sdn Bhd Over 3 Tranches
30 Aug 2023 Media Release: Nabota® successfully registered in Malaysia
17 Aug 2023 Announcement: Results Briefing 1H 2023
11 Aug 2023 Financial Statements and Related Announcement: Half Yearly Results
11 Aug 2023 Cash Dividend / Distribution: Mandatory
19 Jul 2023 Change of Substantial Shareholder’s Interest – Inomed Holding Pte Ltd
19 Jul 2023 Change of Director’s Interest – Mr Lim See Wah
19 Jul 2023 Change of Director’s Interest – Dr Tan Kia King
19 Jul 2023 Cessation of Substantial Shareholder’s Interest – Mr Tan Chwee Choon
05 Jun 2023 (Board Approval) Hyphens Pharma International – Appointment of CFO
24 May 2023 Announcement: Minutes of Annual General Meeting and Extraordinary General Meeting held on 26 April 2023
17 May 2023 Announcement: Hyphens Pharma to develop and commercialise Byfavo procedural sedation drug in Singapore
11 May 2023 Announcement: Business Update and Results Briefing for the First Quarter Ended 31 March 2023
28 Apr 2023 Employee Stock Option / Share Scheme: Allotment and Issuance of 422,000 New Ordinary Shares Under the Hyphens Performance Share Plan
26 Apr 2023 Results of Extraordinary General Meeting held on 26 April 2023
26 Apr 2023 Results of Annual General Meeting held on 26 April 2023
21 Apr 2023 Response to Queries from SIAS on Annual Report 2022
21 Apr 2023 Response to Substantial and Relevant Questions Received from Shareholders before Annual General Meeting
10 Apr 2023 Announcement of Cessation: Cessation of an Executive Director
10 Apr 2023 Cash Dividend / Distribution: Mandatory (FY2022)
10 Apr 2023 Notice of Extraordinary General Meeting
10 Apr 2023 Notice of Annual General Meeting (FY2022)
10 Apr 2023 Annual Reports and Related Documents
06 Mar 2023 Announcement: Results Briefing FY2022
28 Feb 2023 Financial Statements and Related Announcement: Full Yearly Results
10 Feb 2023 Media Release: Nabota® Successfully Registered in Singapore
21 Dec 2022 Media Release: Hyphens Pharma licenses Winlevi® for all 10 ASEAN countries from Cosmo Pharmaceuticals
05 Dec 2022 Media Release: Hyphens Pharma’s Meradan® Cream Launches in Indonesia
09 Nov 2022 Announcement: Quarterly Business Update for the Third Quarter and Nine Months Ended 30 September 2022
15 Sep 2022 Announcement: Hyphens Pharma’s TDF Blu Voile Sunscreen
17 Aug 2022 Announcement: Results Briefing 1H2022
11 Aug 2022 Financial Statements and Related Announcement: Half Yearly Results
06 Jun 2022 Announcement: Completion of Investment in DocMed Technology
31 May 2022 Sustainability Report 2021
27 May 2022 Corporate Presentation – DocMed
27 May 2022 Hyphens Attracts S$6 million Investment in DocMed Technology to Grow Digital Healthtech
12 May 2022 Announcement: Quarterly Business Update for the First Quarter Ended 31 March 2022
06 May 2022 Announcement of Cessation: Resignation of Chief Financial Officer
27 Apr 2022 Results and Minutes of Annual General Meeting held on 27 April 2022
21 Apr 2022 Response to Substantial and Relevant Questions Received from Shareholders before Annual General Meeting
12 Apr 2022 Cash Dividend / Distribution: Mandatory
12 Apr 2022 Notice of Annual General Meeting
12 Apr 2022 Annual Reports and Related Documents
02 Mar 2022 General Announcement: Results Briefing FY2021
23 Feb 2022 Financial Statements and Related Announcement: Full Yearly Results
26 Jan 2022 Change in Corporate Information: Change of Address of Share Registrar
13 Jan 2022 General Announcement: Corporate Presentation
10 Jan 2022 Hyphens Pharma Officially Launches WellAway, Singapore’s First HSA-Registered e-Pharmacy
14 Dec 2021 Hyphens Pharma Has Inked Exclusive Licensing Deal of Ustekinumab Biosimilar
09 Dec 2021 Asset Acquisitions and Disposals: Striking-Off of Indirect Wholly-Owned Subsidiary, DAC Pharmalab Pte Ltd
03 Dec 2021 Change of Director’s Interest – Mr Tan Chwee Choon
03 Dec 2021 Change of Director’s Interest – Dr Tan Kia King
03 Dec 2021 Change of Director’s Interest – Mr Lim See Wah
03 Dec 2021 Change of Substantial Shareholder’s Interest – Inomed Holding Pte Ltd
03 Dec 2021 Asset Acquisitions and Disposals: Completion of the Proposed Acquisition of 100% of the Issued Share Capital in Novem Group
19 Nov 2021 General Announcement: Receipt of Approval In-Principle from SGX-ST for the Listing and Quotation for New Ordinary Shares
16 Nov 2021 General Announcement: Acquisition of Novem & 3Q Business Update
12 Nov 2021 General Announcement: Quarterly Business Update for the Third Quarter and Nine Months Ended 30 September 2021
09 Nov 2021 Request for Lifting of Trading Halt
09 Nov 2021 Asset Acquisitions and Disposals: Entry into a Sale and Purchase Agreement Relating to the Proposed Acquisition
08 Nov 2021 Request for Trading Halt
10 Sep 2021 Change of Director’s Interest – Mr Lim See Wah
10 Sep 2021 Change of Substantial Shareholder’s Interest – Inomed Holding Pte Ltd
18 Aug 2021 General Announcement: Results Briefing 1H2021
11 Aug 2021 Financial Statements and Related Announcement: Half Yearly Results
17 May 2021 Sustainability Report 2020
12 May 2021 Change in Continuing Sponsor
12 May 2021 Quarterly Business Update: 1Q2021
28 Apr 2021 Results and Minutes of Annual General Meeting held on 28 April 2021
13 Apr 2021 Notice of Annual General Meeting
12 Apr 2021 Cash Dividend / Distribution: Mandatory
12 Apr 2021 Annual Reports and Related Documents
19 Mar 2021 Employee Stock Option / Share Scheme: Grant of Share Awards Pursuant to the Hyphens Share Plan
05 Mar 2021 Change of Director’s Interest – Dr Tan Kia King
05 Mar 2021 Change of Director’s Interest – Mr Lim See Wah
05 Mar 2021 Change of Substantial Shareholder’s Interest – Inomed Holding Pte Ltd
03 Mar 2021 General Announcement: Results Briefing FY2020
25 Feb 2021 Financial Statements and Related Announcement: Full Yearly Results
18 Jan 2021 Hyphens Pharma Appoints Exclusive Distributor in South Korea for TDF Fairence® T-Complex
07 Jan 2021 Hyphens Pharma Awarded e-Pharmacy Licence for WellAway Pharmacy
16 Nov 2020 General Announcement: Results Briefing 3Q2020
12 Nov 2020 Hyphens Pharma Broadens Ceradan Brand’s Outreach to Mainland China
11 Nov 2020 Financial Statements and Related Announcement: Third Quarter Results
05 Nov 2020 General Announcement: Change in Composition of the Board of Directors and Board Committees
05 Nov 2020 Announcement of Appointment: Appointment of an Independent Non-Executive Director
03 Nov 2020 Hyphens Pharma Expands Ocean Health Distribution to Sri Lanka
03 Sep 2020 Corporate Presentation
18 Aug 2020 Intangible Asset Portfolio Review
18 Aug 2020 General Announcement: Results Briefing 2Q2020
17 Aug 2020 Hyphens Pharma Inks Exclusive Partnership with SUTL to Distribute Ocean Health Products
13 Aug 2020 Financial Statements and Related Announcement: Second Quarter and/or Half Yearly Results
03 Aug 2020 Corporate Presentation at ASEAN Regional Healthcare Conference by DBS
03 Aug 2020 Hyphens Pharma Expands Proprietary Brands Portfolio with Hair Loss Products
24 Jul 2020 Change of Director’s Interest – Mr Tan Chwee Choon
22 Jul 2020 Change of Director’s Interest – Mr Tan Chwee Choon
15 Jul 2020 Change of Director’s Interest – Mr Tan Chwee Choon
13 Jul 2020 Hyphens Pharma Receives UK Patent for Ceradan Advanced
24 Jun 2020 Change of Director’s Interest – Mr Tan Chwee Choon
12 Jun 2020 Results and Minutes of Annual General Meeting held on 12 June 2020
08 Jun 2020 Response to Queries from SIAS on Annual Report 2019
02 Jun 2020 Change of Director’s Interest – Mr Tan Chwee Choon
01 Jun 2020 Change of Director’s Interest – Mr Tan Chwee Choon
26 May 2020 Sustainability Report 2019
21 May 2020 Notice of Annual General Meeting
14 May 2020 General Announcement: Results Briefing 1Q2020
11 May 2020 Cash Dividend / Distribution: Mandatory
11 May 2020 General Announcement: Update on FY2019 Proposed Final Dividend of S$0.01 per Share
11 May 2020 Financial Statements and Related Announcement: First Quarter Results
28 Apr 2020 Response to Query Regarding Trading Activity
27 Apr 2020 General Announcement – Voluntary Continuation of Quarterly Reporting and Deferment of Half-Yearly Reporting
17 Apr 2020 General Announcement: Change in Composition of the Board of Directors and Board Committees
17 Apr 2020 Announcement of Cessation: Resignation of an Independent Director
09 Apr 2020 General Announcement: Business Continuity During Covid-19 Pandemic
08 Apr 2020 Waiver: Extension of Time to Hold Annual General Meeting for Financial Year Ended 31 December 2019
08 Apr 2020 Annual Reports and Related Documents
03 Mar 2020 General Announcement: Hyphens Results Briefing FY2019
26 Feb 2020 Financial Statements and Related Announcement: Full Yearly Results
06 Feb 2020 General Announcement: TDF Fairence T-Complex has efficacy tests affirmed in Journal of Cosmetic Dermatology
17 Dec 2019 General Announcement: Hyphens Pharma inks Research Collaboration Agreement with the Institute of Chemical and Engineering Sciences
19 Nov 2019 General Announcement: Hyphens Results Briefing 3Q2019
14 Nov 2019 Financial Statements and Related Announcement: Third Quarter Results
05 Nov 2019 Announcement of Cessation: Resignation of General Manager
30 Aug 2019 Announcement of Appointment: Appointment of Chief Operating Officer
19 Aug 2019 General Announcement: Hyphens Results Briefing 2Q2019
13 Aug 2019 Financial Statements and Related Announcement: Second Quarter and/or Half Yearly Results
29 Jul 2019 Announcement of Appointment: Appointment of an Independent Non-Executive Director
22 Jul 2019 General Announcement: Ocean Health revamped, unveils new and refreshed look
10 Jul 2019 General Announcement: Hyphens Pharma launches New Ceradan Advanced
17 Jun 2019 General Announcement: Hyphens Pharma first to introduce bioabsorbable metallic implants to Vietnam
30 May 2019 General Announcement: Hyphens Pharma Signs Exclusive Distribution Agreement with Lundbeck for Vietnam
17 May 2019 General Announcement: Corporate Presentations – Hyphens Results Briefing 1Q2019
17 May 2019 General Announcement: Corporate Presentations – Hyphens Presentation Deck
17 May 2019 General Announcement: Corporate Presentations
15 May 2019 Employee Stock Option / Share Scheme: Grant of Share Awards Pursuant to the Hyphens Share Plan
13 May 2019 Financial Statements and Related Announcement: First Quarter Results
26 Apr 2019 Annual General Meeting: Results and Presentation Slides
18 Apr 2019 Asset Acquisitions and Disposals: Striking-Off Of Indirect Wholly-Owned Subsidiary – Ocean Healthcare (M) Sdn. Bhd.
10 Apr 2019 Notice of Annual General Meeting
10 Apr 2019 Annual Reports and Related Documents
10 Apr 2019 Cash Dividend/Distribution: Mandatory
21 Mar 2019 General Announcement: Hyphens Pharma Officially Opens Corporate Headquarters and Integrated Facility
06 Mar 2019 General Announcement: Hyphens Results Briefing 4Q2018 / FY2018
28 Feb 2019 Financial Statements and Related Announcement: Full Yearly Results
18 Feb 2019 General Announcement: Hyphens Pharma appoints Industry Veteran to head Dermatology Business Unit
05 Dec 2018 General Announcement: Entry into Memorandum of Understanding with Doctor Anywhere
13 Nov 2018 Financial Statements and Related Announcement: Third Quarter Results
29 Sep 2018 Change in Corporate Information: Change of Registered Office
29 Aug 2018 General Announcement: Corporate Presentation at INVEST Fair 2018
10 Aug 2018 Financial Statements and Related Announcement: Second Quarter and/or Half Yearly Results
23 May 2018 General Announcement: Tenancy Agreement with RBC Investor Services Trust Singapore Limited
18 May 2018 General Announcement: Balloting Result under Public Offer of Related Persons
18 May 2018 Disclosure of Interest/Changes in Interest of Director/Chief Executive Officer: Disclosure of interest by Executive Chairman and CEO – Mr Lim See Wah
18 May 2018 Disclosure of Interest/Changes in Interest of Director/Chief Executive Officer: Disclosure of interest by Executive Director – Mr Tan Chwee Choon
18 May 2018 Disclosure of Interest/Changes in Interest of Director/Chief Executive Officer: Disclosure of interest by Non-Executive Director – Dr Tan Kia King
18 May 2018 Disclosure of Interest/Changes in Interest of Substantial Shareholder(s)/Unitholder(s): Disclosure of interest by substantial shareholder – Inomed Holding Pte Ltd
18 May 2018 General Announcement: Hyphens Pharma International Makes Strong Listing Debut on the Catalist Board of the SGX-ST
17 May 2018 Equity – Listing Confirmation: Admission of 300,000,000 ordinary shares to the Official List of SGX-Catalist
17 May 2018 General Announcement: Balloting Results